Drug Approval | February 19, 2022
US FDA to review Amylyx new drug application for AMX0035
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
Darolutamide is developed jointly by Bayer and Orion Corporation
With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
Subscribe To Our Newsletter & Stay Updated
